豐城控股(02295.HK)2021年經調整溢利及全面收益總額約3830萬港元 同比增加5.1%
格隆匯3月23日丨豐城控股(02295.HK)公吿,2021年12月31日止年度收入約為2.939億港元,增幅約6.5%;年內溢利及全面收益總額約為2780萬港元,同比大幅減少約29.3%。年度經調整溢利及全面收益總額(不包括轉板上市以及相關開支以及防疫抗疫基金的財務支援)約為3830萬港元,同比增加5.1%。董事會已議決建議不就截至2021年12月31日止年度宣派末期股息(2020年:無)。
集團的收益增加主要由於截至2021年12月31日止年度為集團帶來收益的項目數量增加及集團來自相對較大規模項目的收益增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.